Evaxion A/S (EVAX) vs Genenta Science S.p.A. (GNTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evaxion A/S (EVAX) has outperformed Genenta Science S.p.A. (GNTA) over the past year, losing 51.5% versus a loss of 78.4%. Genenta Science S.p.A. is the larger company by market cap ($34.2 million vs $27.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | GNTA |
|---|---|---|
| Share price | $3.05 | $0.7101 |
| Market cap | $27.52M | $34.24M |
| 1-day change | -2.87% | -5.95% |
| YTD return | -36.06% | -52.34% |
| 1-year return | -51.51% | -78.35% |
| 5-year return | -99.23% | — |
| EPS (TTM) | $-1.00 | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.15 | $10.00 |
| 52-week low | $2.77 | $0.55 |
| Distance from 52-week high | -74.90% | -92.90% |
| Analyst consensus | none | — |
| Avg. price target upside | +268.85% | — |
| Average volume | 199.49K | 61.48K |
| Shares outstanding | 9.02M | 48.22M |
| Employees | 46 | 9 |
| Sector | Healthcare | Industrials |
| Industry | Biotechnology | Conglomerates |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EVAX has outperformed GNTA by 26.8 percentage points over the past year.
- The two companies sit in different sectors: Evaxion A/S in Healthcare and Genenta Science S.p.A. in Industrials.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
About Genenta Science S.p.A.
GNTA stock →Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.
Industrials · Conglomerates · 9 employees
EVAX vs GNTA FAQ
Which is bigger, Evaxion A/S or Genenta Science S.p.A.?
Genenta Science S.p.A. (GNTA) is larger, with a market capitalization of $34.24M compared with $27.52M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, EVAX or GNTA?
EVAX returned -51.51% over the past 12 months, compared with -78.35% for GNTA (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and Genenta Science S.p.A. in the same industry?
No. Evaxion A/S is in the Healthcare sector, while Genenta Science S.p.A. is in Industrials.